Table 3.
Citrate PK.
| Parameter | Critically ill ALF patients (N = 7) | Critically ill ACLF patients (N = 7) |
|---|---|---|
| AUC0−t (mmol min/L) | 124.4 ± 43.9 | 113.9 ± 73.3 |
| AUC0−inf (mmol min/L) | 267.2 ± 111.7 | 372.6 ± 399.3 |
| Tmax (min) | 100.0 ± 60.0 | 113.8 ± 32.8 |
| Vd (L) | 45.6 ± 8.0 | 58.2 ± 49.7 |
| Clbody (mL/min) | 152.5 ± 50.9 | 195.6 ± 174.3 |
| Cbaseline (mmol/L) | 0.24 ± 0.12 | 0.21 ± 0.12 |
| Cmax (mmol/L) | 0.76 ± 0.27 | 0.72 ± 0.44 |
| Total dose (mmol) | 39.9 | 39.9 |
AUC area under the plasma concentration–time curve, Tmax time to maximum concentration, Vd volume of distribution, Clbody citrate clearance by body, Cbaseline baseline citrate concentration, Cmax maximum citrate concentration.
Data are shown as mean ± SD.